[Elsevier] Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial |
|
This post will be closed automatically in 2026-07-18 06:55
Reward10points
|
post
reply
points
140
10
Mechanistic dissection of SMARCA2/4 molecular glues reveals programmable switching between DCAF16 and FBXO22
10
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
10
Studies on heterogeneous cation-exchange membranes
10
Editorial Article for the Virtual Special Issue: Celebrating the 30th anniversary of the Uruguayan Society for Neuroscience: Emergent topics from South America to global neuroscience
10
Glial Cx43 hemichannels and neuronal Panx1 hemichannels and P2X7 receptors orchestrate presynaptic homeostatic plasticity
